Tanimilast - Chiesi Farmaceutici
Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler®; CHF-6001; CHF6001 DPILatest Information Update: 11 Jul 2024
At a glance
- Originator Chiesi Farmaceutici
- Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Allergic asthma; Asthma
Most Recent Events
- 11 Jul 2024 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Belgium (Inhalation)
- 18 Jun 2024 Chiesi Farmaceutici completes a phase I trial for Chronic obstructive pulmonary disease (In volunteers) in Bulgaria (Inhalation) (NCT06395610)
- 17 May 2024 Adverse events and pharmacokinetics data from a phase I trial in Chronic obstructive pulmonary disease presented at the 120th International Conference of the American Thoracic Society (ATS-2024)